Zhejiang Conba Pharmaceutical

What Zhejiang Conba Pharmaceutical does

Zhejiang Conba Pharmaceutical (浙江康恩贝制药) is a publicly listed Chinese pharmaceutical company (SSE: 600572) headquartered in Hangzhou, Zhejiang, and operating as the core pharmaceutical manufacturing entity of Conba Group (康恩贝集团有限公司), a privately held diversified industrial conglomerate established in 1996 with 324 million RMB registered capital. The company's origins trace to the 1969 Lanxi County Yunshan Pharmaceutical Factory. The pharmaceutical segment develops, manufactures, and sells prescription and OTC drug products spanning cardiovascular, respiratory, and neurological therapeutic areas, distributed through its direct sales force and the dense Zhejiang Zhencheng Pharmaceutical Online distribution network across China. Related subsidiaries include Jiangxi Huabang Pharmaceutical and Zhejiang Yibaoxin Biotechnology, broadening the manufacturing and biotech footprint.

The group operates three industrial pillars: pharmaceutical and biomedical products, waste recycling and resource recovery (through subsidiary Zhejiang Fengdeng Green Energy Environmental Protection), and modern agriculture. Conba Group pursues a licensing-driven model for innovative drug pipeline expansion, exemplified by the Cebrenopadol licensing agreement with AdNeuris Therapeutics and the broader $17.5 million upfront plus up to $94 million milestone licensing deal with Adnexus for Greater China commercialization rights. Conba Group is diversifying into adjacent verticals, with Fengdeng Green Energy holding world-pioneering organic hazardous waste treatment technology and pursuing a 'Flying Across Nine Provinces' national expansion plan that includes new sites in Shangyu and Weifang, supported by strategic financing from China Petroleum Capital.

The business model spans four revenue streams: pharmaceutical manufacturing and sales (prescription/OTC), pharmaceutical wholesale and retail distribution, organic hazardous waste recycling and resource recovery services through Fengdeng Green Energy, and licensing royalties from in-licensed innovative compounds. Customer reach is anchored by a domestic China distribution network with manufacturing bases in Jinhua, Hangzhou, Shaoxing, and Yunnan provinces. The group holds multiple national recognitions including a National Specialized, Refined, and Innovative Small Giant Enterprise designation, two China Environmental Protection Science and Technology Awards, and listings in the National Low-Carbon Technology Catalog.

Name

Zhejiang Conba Pharmaceutical

Legal name

康恩贝集团有限公司

Website

https://conbagroup.com

Company type

Private

Founded year

1996

Operating status

Operating

Short description

Zhejiang Conba Pharmaceutical is a publicly listed Chinese pharmaceutical company (SSE: 600572) manufacturing and distributing prescription and OTC drugs across cardiovascular, respiratory, and neurological therapeutic areas, serving patients and healthcare providers in China via direct sales and an extensive distribution network.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Chemical and Allied Products Merchant Wholesalers (4246)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industries

Specialty Pharmaceutical Distributors (HLAIAJAB), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Pharmaceutical manufacturing
• Pharmaceutical distribution
• Prescription drug development
• Waste recycling services
• Drug licensing

Headquarters

HQ city

Hangzhou

HQ country

China

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Manufacturing and Sales: Revenue from manufacturing and selling prescription and OTC pharmaceutical products through subsidiary Zhejiang Conba Pharmaceutical and other pharmaceutical subsidiaries. Core drug varieties drive market expansion and R&D innovation.
2. Pharmaceutical Distribution: Revenue from wholesale and retail distribution of pharmaceutical products through Zhejiang Zhencheng Pharmaceutical Online, providing a dense health services network across China.
3. Waste Recycling and Resource Recovery: Revenue from Fengdeng Green Energy (凤登绿能环保股份有限公司) for organic hazardous waste collection, treatment, and resource recovery services. The subsidiary has developed a national 'specialized, refined, and innovative small giant enterprise' position.
4. Licensing Royalties: Revenue from milestone payments and royalties on net sales from licensed products developed and commercialized in Greater China under licensing agreements.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Core offering

Zhejiang Conba Pharmaceutical operates a diversified industrial group whose core business is pharmaceutical manufacturing and sales of prescription and OTC drugs through subsidiary Zhejiang Conba Pharmaceutical Co., Ltd. (SSE: 600572), supported by pharmaceutical distribution via Zhejiang Zhencheng Pharmaceutical Online. The group also derives revenue from organic hazardous waste treatment and resource recovery through Zhejiang Fengdeng Green Energy Environmental Protection and from modern agriculture, while expanding its innovative drug pipeline through Greater China in-licensing deals with international partners such as AdNeuris Therapeutics and Adnexus.

Product overview

Zhejiang Conba Pharmaceutical Group operates as a diversified industrial group with three main business pillars: (1) Pharmaceutical/biomedical sector including Zhejiang Conba Pharmaceutical, Zhejiang Zhencheng Medicine Online, Jiangxi Huabang Pharmaceutical, and Zhejiang Yibaixin Biotechnology; (2) Waste recycling and resource recovery represented by Zhejiang Fengdeng Green Energy Environmental Protection; and (3) Modern agriculture. The group also has strategic partnerships for innovative drug development, including licensing agreements for novel compounds like Cebrenopadol from AdNeuris Therapeutics for Greater China markets.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 省级智能工厂认定 — Fengdeng Green Energy recognized as a provincial-level smart factory.
• +2 more outcomes

Segments1 record

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature2 records

Partnerships

Three partnerships are on record, tiered core.

• AdNeuris TherapeuticscoreOEM/ Whitelabel/ Licensing Partner · 6 July 2026Zhejiang Conba Pharmaceutical's subsidiaries signed a licensing agreement with AdNeuris Therapeutics to obtain Greater China development and commercialization rights for Cebrenopadol, a novel compound with potential applications in pain management and other therapeutic areas including neurological treatments. This deal enhances Zhejiang Conba's portfolio in the pharmaceutical sector and reflects strategic focus on expanding innovative drug development through international partnerships.
• AdnexuscoreOEM/ Whitelabel/ Licensing Partner · 6 July 2026Zhejiang Conba Pharmaceutical announced it will pay Adnexus a $17.5 million upfront payment, with additional potential payments of up to $94 million tied to development and commercial milestones, plus royalties on net sales. The deal structure indicates a licensing or collaboration agreement for the development and commercialization of a pharmaceutical compound in Greater China.
• Zhejiang University (浙江大学)coreStrategic or Co-development Partner康恩贝集团 has deepened industry-academia-research cooperation with Zhejiang University, one of China's top universities. The group's innovation platform's carrying capacity and creativity have significantly improved through this ongoing collaboration, supporting the group's technology R&D '尖兵力量' (elite force) in converting to market competitive advantages.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Livzon Pharmaceutical Group: Diversified Chinese pharmaceutical group with branded prescription, OTC, and API businesses, plus a sizable distribution arm. Comparable in the integration of manufacturing and distribution within a publicly listed structure.
• Yunnan Baiyao Group: Chinese pharmaceutical conglomerate combining branded TCM/OTC products, manufacturing, and consumer health distribution. Closely comparable to Zhejiang Conba's mix of branded pharma manufacturing plus proprietary distribution.
• Fosun Pharma: Diversified Chinese pharmaceutical group combining manufacturing, distribution, and diagnostic/healthcare services with active international licensing. Highly comparable diversified industrial structure to Conba Group.
• Guangzhou Baiyunshan Pharmaceutical: Chinese pharmaceutical and healthcare products company combining branded pharma manufacturing, OTC/consumer health, and distribution. Similar in business architecture and reliance on traditional plus innovative channels.
• Zhejiang Huahai Pharmaceutical: Zhejiang-based Chinese specialty pharmaceutical manufacturer with a comparable mix of branded generics, CNS/cardiovascular products, and active international licensing partnerships. Similar in scale and regional footprint to Zhejiang Conba Pharmaceutical.

Broad incumbents

• Shanghai Pharmaceuticals Holding: One of China's largest pharmaceutical distributors and manufacturers, with a dense national distribution network analogous to Zhencheng Medicine Online and broad branded pharma manufacturing. Larger scale but directly comparable business model.
• China Resources Pharmaceutical Group: Major state-backed Chinese pharmaceutical manufacturer and distributor with extensive commercial channels. Overlaps with Zhejiang Conba on both manufacturing and distribution, though at substantially larger scale.
• Sino Biopharmaceutical: Large Hong Kong-listed Chinese pharmaceutical company with a broad branded and specialty pharma portfolio including CNS, respiratory, and cardiovascular products. Comparable therapeutic area coverage and prescription/OTC mix.
• Jiangsu Hengrui Pharmaceuticals: China's largest innovative-drug-focused pharmaceutical manufacturer with strong CNS and oncology pipelines. Comparable to Zhejiang Conba's specialty pharma manufacturing ambitions and licensing-driven pipeline expansion.
• CSPC Pharmaceutical Group: Major Chinese pharmaceutical manufacturer with significant CNS/neurology franchise and innovative drug pipeline. Directly comparable on therapeutic focus and pipeline-driven growth profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/zhejiang-conba-pharmaceutical-co-ltd-

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zhejiang Conba Pharmaceutical